Mild stimulation in in vitro fertilization

Annals of the New York Academy of Sciences

Volumn 997, Issue , 2003, Pages 105-111

  Macklon, N S ^a   Fauser, B C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Follicle selection; Follicle stimulating hormone (FSH) window; in vitro fertilization (IVF); Mild stimulation

Indexed keywords

GONADORELIN ANTAGONIST; FERTILITY PROMOTING AGENT; GONADORELIN; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; EMBRYO DEVELOPMENT; EMBRYO TRANSFER; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; MULTIPLE PREGNANCY; OOCYTE; OVARY FOLLICLE CELL; OVULATION INDUCTION; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; FOLLOW UP; METHODOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; MENOTROPINS; OOCYTES; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; PREGNANCY, MULTIPLE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0642272538     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1290.012     Document Type: Conference Paper

References (30)

1. TEMPLETON, A. & J.K. MORRIS. 1998. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. N. Engl. J. Med. 339: 573-577.
2. BEERENDONK, C.C.M. et al. 1998. Ovarian hyperstimulation syndrome: facts and fallacies. Obstet. Gynecol. Surv. 53: 439-449.
3. TARLATZIS, B.C. et al. 1995. Ovarian stimulation and ovarian tumours: a critical reappraisal. Hum. Reprod. Update 1: 284-301.
4. BRISTOW, R.E. & B.Y. KARLAN. 1996. Ovulation induction, infertility, and ovarian cancer risk. Fertil. Steril. 66: 499-507.
5. MACKLON, N.S. & B.C.J.M. FAUSER. 2000. Impact of ovarian hyperstimulation on the luteal phase. J. Reprod. Fertil. 55: 101-108.
6. VAN DER GAAST, M. et al. 2002. Ovarian stimulation for IVF and endometrial receptivity: the missing link. Reprod. Bio. Online 5(Suppl. 1): 36-43.
7. KOLIBIANAKIS, E.M. & P. DEVROEY. 2002. The luteal phase after ovarian stimulation. Reprod. Bio. Online 5(Suppl. 1): 26-35.
8. NYGREN, K.G. & A.N. ANDERSEN. 2001. Assisted reproductive technology in Europe, 1997. Results generated from European registers by ESHRE. European IVF-Programme (EIM), for the European Society of Human Reproduction and Embryology (ESHRE). Hum. Reprod. 16: 384-391.
9. NYGREN, K.G. & A.N. ANDERSEN. 2001. Assisted reproductive technology in Europe, 1998. Results generated from European registers by ESHRE. European Society Human Reproduction and Embryology. Hum. Reprod. 16: 2459-2471.
10. AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE/SOCIETY FOR ASSISTED REPRODUCTIVE TECHNOLOGY REGISTRY. 2000. Assisted Reproductive Technology in the United States: 1997 results. Fertil. Steril. 74: 641-653.
11. AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE/SOCIETY FOR ASSISTED REPRODUCTIVE TECHNOLOGY REGISTRY. 2002. Assisted Reproductive Technology in the United States: 1998 results. Fertil. Steril. 77: 18-31.
12. THE ESHRE CAPRI WORKGROUP GROUP. 2000. Multiple gestation pregnancy. Hum. Reprod. 15: 1856-1864.
13. WøLNER-HANSSEN, P. & H. RYDHSTROEM. 1998. Cost-effectiveness analysis of in-vitro fertilization: estimated costs per successful pregnancy after transfer of one or two embryos. Hum. Reprod. 113: 88-94.
14. GERRIS, J. et al. 1999. Prevention of twin pregnancy after in-vitro fertilization or intracytoplasmic sperm injection based on strict embryo criteria: a prospective randomized clinical trial. Hum. Reprod. 14: 2581-2587.
15. DE JONG, D. et al. 2002. The added value of embryo crypreservation to cumulative ongoing pregnancy rats per IVF treatment: is cryopreservation worth the effort? J. Assist. Reprod. Genet. 19: 561-568.
16. FAUSER, B.C.J.M. et al. 1999. Mild ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum. Reprod. 14: 2681-2686.
17. FAUSER, B.C.J.M. & A.M. VAN HEUSDEN. 1997. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr. Rev. 18: 71-106.
18. PACHE, T.D. et al. 1990. Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. Fertil. Steril. 54: 638-642.
19. VAN SANTBRINK, E.J. et al. 1995. Decrementai follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertil. Steril. 64: 37-43.
20. BAIRD, D.T 1987. A model for follicular selection and ovulation: lessons from superovulation. J. Steroid. Biochem. 27: 15-23.
21. FAUSER, B.C.J.M. et al. 1993 The step-down principle in gonadotrophin treatment and the role of GnRH analogues. Baillières Clin. Obstet. Gynaecol. 7: 309-330.
22. MACKLON, N.S. & B.C.J.M. FAUSER. 1999. Aspects of ovarian follicle development throughout life. Horm. Res. 52: 161-170.
23. SCHIPPER, I. et al. 1998. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration rather than magnitude of FSH increase affects follicle development. J. Clin. Endocrinol. Metab. 83: 1292-1298.
24. HOHMANN, F. et al. 2001. Low dose exogenous FSH initiated during the early, mid, or late follicular phase can induce dominant follicle development. Hum. Reprod. 16: 846-854.
25. BOUCHARD, P. & B.C.J.M. FAUSER. 2000. GnRH antagonists: new tools versus old habits. Fertil. Steril. 73: 18-20.
26. HALL, J.E. 1993. Gonadotropin-releasing hormone antagonists: effects on the ovarian follicle and corpus luteum. Clin. Obstet. Gynecol. 36: 744-752.
27. DE JONG, D. et al. 2000. A pilot study involving mild ovarian stimulation for in vitro fertilization: extending the 'follicle-stimulating hormone window' combined with the gonadotrophin-releasing hormone antagonist cetrorelix. Fertil. Steril. 73: 1051-1054.
28. SCHIPPER, I. et al. 1998. Lack of correlation between maximum early follicular phase serum follicle-stimulating hormone concentrations and menstrual cycle characteristics in young normo-ovulatory women. Hum. Reprod. 13: 1442-1448.
29. DEVROEY, P. et al. 1998. The use of 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Hum. Reprod. 13: 565-566.
30. HOHMANN, F. et al. 2003. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with standard long GnRH agonist protocol. J. Clin. Endorinol. Metab. 88: 166-173.